Elevated Levels of Furan Fatty Acid Metabolite in MS

Share this content:
Elevated levels of CMPF, which has been linked to beta cell dysfunction in diabetes and thyroid disorders, have been identified in patients with MS.
Elevated levels of CMPF, which has been linked to beta cell dysfunction in diabetes and thyroid disorders, have been identified in patients with MS.

The endogenous metabolite of furan fatty acid, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is a naturally occurring lipid that is excreted into the urine in patients with multiple sclerosis (MS) and healthy individuals.  It has been found to accumulate at high concentrations in the serum of uremic patients. It is albumin bound and has been reported to inhibit cellular transport, erythropoiesis, and mitochondrial respiration

Researchers have identified elevated CMPF levels in the cerebrospinal fluid (CSF) of patients with progressive MS, as reported in a presentation at the 2016 annual meeting of the American Academy of Neurology (AAN).

Using metabolite screening, CSF and blood samples were obtained from patients with MS (n=183) and healthy controls (n=38) and CMPF levels were assessed. Serum CMPF levels were found to be significantly elevated in the MS patients (P<.0001), with a more pronounced increase in patients with primary progressive MS compared with those with the relapsing-remitting form of the disease. 

The researchers also found that elevations in CMPF level correlated with MS disease activity but did not vary with regard to gender.

The results of this study, which is the first to report increased CMPF levels in MS, warrant further investigation of the role of this furan fatty acid metabolite in the pathogenesis of MS.

Click here for more coverage from the 68th Annual Meeting of the American Academy of Neurology, April 15-21, 2016, in Vancouver, British Columbia, Canada.

Reference

  1. Blemur D, Mir F, Sadiq S. Elevated levels of the furan fatty acid metabolite, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in the serum of multiple sclerosis patients. Presented at: The 68th Annual Meeting of the American Academy of Neurology; April 15-21, 2016; Vancouver, British Columbia, Canada. Poster P1.368.
You must be a registered member of Neurology Advisor to post a comment.